Chances are not many of us observed New Year’s Eve with celebratory toasts to the glorious year gone by. Rather, we bid goodbye to 2018 and hoped 2019 would be a better year – for ourselves, our near and dear, our country, and our planet. However, as I wade through the volumes of healthcare-related stuff […]
I’ll grant that my headline is meant to be catchy and induce you to read this epistle. Some of you will ask what is ketamine anyway, and most of you will know from the get-go that ketamine, whatever the heck it is, will turn out to be neither a menace nor a miracle, but something […]
Let’s lead off with a news item that Doc Gumshoe, despite his widely-acknowledged acumen, could not manage to figure out in the least. It took an Op Ed in the N Y Times to sweep the cobwebs out of his noggin. The news item was this: children born in the month of August […]
I’m not going to keep you in suspense. The two proposed miracle cures are L-carnitine (an amino acid) and “Delta 8,” which in a previous Doc Gumshoe disquisition was unmasked as Delta 8 tetrahydrocannabinol, or Delta 8 THC (Δ8 THC), which is one of perhaps a hundred cannabinoids found in the cannabis plant, as […]
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
For those of us who live in this part of the country and spend any time messing around outdoors in the grass and weeds, this is the time to be careful about Lyme disease. I had a bout of Lyme 16 years ago, and it descended on me when we were on vacation, driving through […]
Is this going to be good news, or bad news, or somewhere in between? On balance, I would say good news, simply because the research and investigation is going on at an intense pace. Currently there are 1,903 clinical trials underway at some stage, in the US and all over the world. When I first […]
When I last took a look at what was happening in the treatment of migraines, I took careful pains to elucidate the differences between migraines and a plain old bad headache – the fact that migraines affect only one side of the head, and a detailed disquisition on the symptoms that many migraineurs (that’s the […]
The last time osteoporosis came up in the gospel according to Doc Gumshoe it was in the context of “not good news.” Starting in the year 2002, there had been a steady decline in the number of hip fractures sustained by women on Medicare over the age of 65, from 931 per 100,000 in 2002 […]
The only reason I accepted his invitation to circle the dance floor is that his latest foray into temptation has to do with pluripotent stem cells, a highly interesting, extremely complex, and promising area of serious scientific investigation. But before I attempt to follow Dr Sears’ complicated dance routine, there’s another bit of news that […]
No, these bits won’t be about Melania’s kidney ailment nor yet about what Meghan wore for The Wedding. I wish them both luck – they’ll need it!. However, there continue to be developments on the medical and health-care fronts that may matter to us a good deal more than the doings of those ladies. […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investments. His ideas, thoughts and words are his own, […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues, marketing, and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues, marketing, and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our […]